The efficacy of tropifexor in MASH has been examined in a phase 2 RCT, in which a 12–48-week intervention of this FXR agonist resulted in a dose-dependent reduction in ALT level in patients (−10.7 to −23.0 U/L under dosages ranging from 10 to 200 μg) [125]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.